ESMO20: PROfound trial concludes olaparib should become the new standard treatment for prostate cancer

Written by Louis Gautier, Future Science Group


The final analysis of the trial (NCT02987543), presented at the ESMO Virtual Congress 2020 and published in The New England Journal of Medicine, concludes that olaparib (Lynparza®) is more effective in extending survival for advanced prostate cancer than current standard hormone therapies. The PROfound trial, co-led by The Institute of Cancer Research (ICR; London, UK) and The Royal Marsden NHS Foundation Trust (London, UK) and funded by AstraZeneca (MD, USA), sought to evaluate the PARP inhibitor, olaparib, in men with metastatic castration-resistant prostate cancer with disease progression receiving enzalutamide (Xtandi®) or abiraterone (Zytiga®). The study recruited 387 men with advanced...

To view this content, please register now for access

It's completely free